New Antithrombotic Drugs *
Henderson Research Center, McMaster University, 711 Concession Street, Hamilton, Ontario, Canada. Chest
(Impact Factor: 7.48).
06/2008; 133(6 Suppl):234S-256S. DOI: 10.1378/chest.08-0673
This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.
Available from: Ayman Hamdan Mansour
- "The purpose of this study was to investigate the effectiveness of using various methods of sheath removal among patient post cardiac catherization. In Jordan, it is important to mention that the literature emphasized the expected high cost spent to manage complication of invasive cardiac interventions , in spite of development of evidence-based guideline for PCI . The results, in general, showed that manual sheath removal is the most used method as about 95% of them had this method. "
Available from: Alexander G G Turpie
- "Factor Xa inhibitors bind directly to the active site of factor Xa to inhibit thrombin generation. These agents have initiated a new era for anticoagulation therapy, due in part to the convenience of oral administration and to their predictable pharmacokinetic and pharmacodynamic properties compared with traditional agents [Weitz et al. 2008]. VKAs, such as warfarin, have a narrow therapeutic range, require regular monitoring, and present challenges in achieving optimal anticoagulation [Ansell et al. 2008]. "
[Show abstract] [Hide abstract]
ABSTRACT: Arterial and venous thromboembolic diseases are a clinical and economic burden worldwide. In addition to traditional agents such as vitamin K antagonists and heparins, newer oral agents - such as the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and the direct thrombin inhibitor dabigatran - have been shown to be effective across several indications. Rivaroxaban has been shown to have predictable pharmacokinetic and pharmacodynamic properties, including a rapid onset of action. In addition, there is no requirement for routine coagulation monitoring; and no dose adjustment is necessary for age alone, sex, or body weight. Rivaroxaban has successfully met primary efficacy and safety endpoints in large, randomized phase III trials across several indications, including: prevention of venous thromboembolism in orthopedic patients undergoing elective hip or knee replacement surgery; treatment of deep vein thrombosis and secondary prevention of deep vein thrombosis and pulmonary embolism; stroke prevention in patients with atrial fibrillation; and secondary prevention of acute coronary syndrome. Rivaroxaban and the other newer oral anticoagulants are likely to improve outcomes in the prevention and treatment of thromboembolic events, and will offer patients and physicians alternative treatment options.
Available from: Ola E Dahl
- "warfarin) to prevent postoperative VTE after THA or TKA . To address some of the well-known limitations of these established agents, several new oral anticoagulants have been developed , including the direct Factor Xa inhibitor rivaroxaban (Xarelto; Bayer Pharma AG: Berlin, Germany). "
[Show abstract] [Hide abstract]
ABSTRACT: The RECORD programme compared oral rivaroxaban with enoxaparin for prevention of venous thromboembolism after elective total hip or knee replacement. This analysis compared the safety of concomitant use of specified medications with rivaroxaban and enoxaparin by evaluating postoperative bleeding rates from the pooled RECORD1-4 data.
The co-medications were non-steroidal anti-inflammatory drugs and platelet function inhibitors, including acetylsalicylic acid (no dose restriction). The endpoints evaluated were the composite of major and non-major clinically relevant bleeding and any bleeding occurring after first oral study drug intake. The time relative to surgery was stratified into three time periods: day 1-3, day 4-7 and after day 7. Relative bleeding rate ratios for co-medication use versus non-use were derived using stratified Mantel-Haenszel methods and compared between rivaroxaban and enoxaparin groups.
Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events. Respective rate ratios were not significantly different between rivaroxaban and enoxaparin for all bleeding endpoints with concomitant use of non-steroidal anti-inflammatory drugs (any bleeding, 1.22 vs 1.22; major and non-major clinically relevant bleeding, 1.28 vs 0.90) and with concomitant use of platelet function inhibitors/acetylsalicylic acid (any bleeding, 1.32 vs 1.40; major and non-major clinically relevant bleeding, 1.11 vs 1.13).
This explorative analysis indicates that there is no significant increase in bleeding risk for rivaroxaban compared with enoxaparin when co-administered with non-steroidal anti-inflammatory drugs or acetylsalicylic acid, although, because of low usage, the experience with platelet function inhibitors (except acetylsalicylic acid) was limited.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.